Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Cardiff Oncology (CRDF) Shares Outstanding (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Shares Outstanding for 15 consecutive years, with $68.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 2.68% to $68.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $68.3 million through Dec 2025, up 2.68% year-over-year, with the annual reading at $68.3 million for FY2025, 2.68% up from the prior year.
  • Shares Outstanding hit $68.3 million in Q4 2025 for Cardiff Oncology, up from $67.1 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $68.3 million in Q4 2025 to a low of $61000.0 in Q2 2023.
  • Historically, Shares Outstanding has averaged $33.8 million across 5 years, with a median of $41.4 million in 2021.
  • Biggest five-year swings in Shares Outstanding: plummeted 99.86% in 2023 and later skyrocketed 109891.8% in 2025.
  • Year by year, Shares Outstanding stood at $716000.0 in 2021, then surged by 6139.8% to $44.7 million in 2022, then tumbled by 99.86% to $61000.0 in 2023, then soared by 108955.74% to $66.5 million in 2024, then increased by 2.68% to $68.3 million in 2025.
  • Business Quant data shows Shares Outstanding for CRDF at $68.3 million in Q4 2025, $67.1 million in Q3 2025, and $66.5 million in Q2 2025.